MARILYN HOCKENBERRY to Hematinics
This is a "connection" page, showing publications MARILYN HOCKENBERRY has written about Hematinics.
Connection Strength
0.079
-
Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol. 2006 Aug 01; 24(22):3583-9.
Score: 0.064
-
Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. J Support Oncol. 2005 Nov-Dec; 3(6 Suppl 4):10-1.
Score: 0.015